The Role of Tumor Mutational Burden in Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.

Related Videos

November 19, 2014

Managing Oncology Costs in Polycythemia Vera

Listen as Ken Schaecher, MD describes the rule of ACOs in helping to manage oncology costs and how they impact oncology care.Supported through funding from Incyte

December 18, 2018

Financial Constraints to Molecular Biomarker Testing

Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.